

RIFAXIMIN SPECIAL AUTHORIZATION REQUEST FORM

Patients may or may not meet eligibility requirements as established by Alberta government sponsored drug programs.

Please complete all required sections to allow your request to be processed.

PATIENT INFORMATION					COVERAGE TYPE			
AST NAME FIRST NAME				INITIAL		☐ Alberta Blue Cross ☐ Alberta Human Services		
BIRTH DATE (YYYY-MM-DD)	ALBERTA PERSONAL HEALTH NUMBER				Other			
							·	
ADDRESS	CITY	Р	PROV	POST	TAL CODE	ID/CLIEN	NT/COVERAGE NUMBER	
PRESCRIBER INFORMATION								
PRESCRIBER LAST NAME FIRST NAME INITIAL				RIBER	PROFESSIO		OCIATION REGISTRATION	
ADDRESS				☐ CPSA ☐ ACO REGISTRATION NUMBER ☐ CARNA ☐ ADA+C ☐ ACP ☐ Other				
on i, i novinol				THORE				
POSTAL CODE				FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED				
Criteria for Coverage								
<u> </u>	ic Encephalonathy (HE)	(i.e. 2.o	r mor	a anisadas	·) in nati	ents with a diagnosis of	
"For reducing the risk of recurrent Hepatic Encephalopathy (HE) (i.e. 2 or more episodes), in patients with a diagnosis of cirrhosis of the liver or presence of portal hypertension.								
Patients must have tried lactulose and been unable to achieve adequate control of HE recurrence with lactulose alone.								
Rifaximin must be used in combination with a maximal tolerated dose of lactulose.								
Special authorization may be granted for 6 months."								
This product is eligible for auto-renewal.								
Please provide the following information for all requests								
Indication for use (check all that apply)								
☐ To reduce the risk of recurrent Hepatic Encephalopathy (HE)								
→ □ Patient has had 2 or more episodes of HE								
☐ Other, specify								
Previous therapy								
Please indicate if lactulose was tried								
☐ Yes → please indicate response to lactulose ☐ unable to achieve adequate control of HE recurrence								
□ other, specify								
☐ No, specify reason	_		, ,	,				
Concomitant therapy								
Please indicate if rifaximin will be used in combination with a maximal tolerated dose of lactulose								
□ Yes								
☐ No, specify reason								
Additional information relating to request								
Additional information relating to requ	uest							
DDECODIDEDIO CIONATURE	DATE ASSOCIATION	1						
PRESCRIBER'S SIGNATURE	DATE (YYYY-MM-DD)	Pl			s request to ross, Clinica	l Drua Ser	vices	
		10009 10	10009 108 Street NW, Edmor			nton, Alberta T5J 3C5		
ONCE YOUR REQUEST HAS SU	ICCESSEIII LV TRANSI	A1-T-T-					7-828-4106 toll free all other areas	

The information on this form is being collected and pursuant to sections 20, 21 and 22 of the Health Information Act, and sections 33 and 34 of the Freedom of Information and Protection of Privacy Act, for the purposes of determining or verifying eligibility to participate in a program or receive a benefit, product or health service. If you have any questions regarding the collection or use of this information, please contact an Alberta Blue Cross privacy matters representative toll-free at 1-855-498-7302 or write to Privacy Matters, Alberta Blue Cross, 10009 - 108 Street,

Edmonton AB T5J 3C5.

